CN108025067A - 抗血管内皮生长因子受体2（vegfr2）抗体 - Google Patents

抗血管内皮生长因子受体2（vegfr2）抗体 Download PDF

Info

Publication number
CN108025067A
CN108025067A CN201680049578.3A CN201680049578A CN108025067A CN 108025067 A CN108025067 A CN 108025067A CN 201680049578 A CN201680049578 A CN 201680049578A CN 108025067 A CN108025067 A CN 108025067A
Authority
CN
China
Prior art keywords
seq
amino acid
cdr
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680049578.3A
Other languages
English (en)
Chinese (zh)
Inventor
姜伟东
林佩桦
曾琪铃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henlius Biotech Co ltd
Original Assignee
Henlius Biotech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henlius Biotech Co ltd filed Critical Henlius Biotech Co ltd
Publication of CN108025067A publication Critical patent/CN108025067A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
CN201680049578.3A 2015-06-30 2016-06-29 抗血管内皮生长因子受体2（vegfr2）抗体 Pending CN108025067A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187204P 2015-06-30 2015-06-30
US62/187,204 2015-06-30
PCT/US2016/040183 WO2017004254A1 (en) 2015-06-30 2016-06-29 Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies

Publications (1)

Publication Number Publication Date
CN108025067A true CN108025067A (zh) 2018-05-11

Family

ID=57609558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680049578.3A Pending CN108025067A (zh) 2015-06-30 2016-06-29 抗血管内皮生长因子受体2（vegfr2）抗体

Country Status (12)

Country Link
US (1) US20180193456A1 (enExample)
EP (1) EP3316908A4 (enExample)
JP (1) JP2018528759A (enExample)
KR (1) KR20180021136A (enExample)
CN (1) CN108025067A (enExample)
AU (1) AU2016288192A1 (enExample)
BR (1) BR112017027702A2 (enExample)
CA (1) CA2990450A1 (enExample)
HK (1) HK1254048A1 (enExample)
RU (1) RU2018103192A (enExample)
TW (1) TW201718641A (enExample)
WO (1) WO2017004254A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013061A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
CN113480653A (zh) * 2021-08-06 2021-10-08 北京戴域生物技术有限公司 一种含有γδT细胞的药物组合物在治疗癌症中的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
CN106674349B (zh) * 2017-03-07 2018-03-13 北京东方百泰生物科技有限公司 一种改进的抗vegfr‑2单克隆抗体
TWI665213B (zh) * 2017-06-29 2019-07-11 財團法人生物技術開發中心 抗人類血管內皮生長因子受體之抗體及其應用
AU2019239984B2 (en) * 2018-03-20 2023-03-30 National Health Research Institutes Dual-function antibodies targeting VEGFR2 and VEGFR3
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260765A1 (en) * 2007-07-25 2010-10-14 Astrazeneca Ab Targeted binding agents directed to kdr and uses thereof - 035
WO2014055998A1 (en) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Human anti-vegfr-2/kdr antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104151429B (zh) * 2007-11-26 2018-07-10 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
US8128932B2 (en) * 2009-08-17 2012-03-06 Shanghai Aosaiersi Biotech Co., Ltd. Anti-VEGFR monoclonal antibody, method of making and uses thereof
US9029510B2 (en) * 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260765A1 (en) * 2007-07-25 2010-10-14 Astrazeneca Ab Targeted binding agents directed to kdr and uses thereof - 035
WO2014055998A1 (en) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Human anti-vegfr-2/kdr antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JANE KENDREW等: "An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding", 《MOLECULAR CANCER THERAPEUTICS》 *
马英等: "抗新生血管生成药ramucirumab的药理作用及临床评价", 《中国新药杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013061A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
CN114341170A (zh) * 2019-07-19 2022-04-12 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
CN114341170B (zh) * 2019-07-19 2023-09-01 神州细胞工程有限公司 一种人源化抗vegfr2抗体及其应用
CN113480653A (zh) * 2021-08-06 2021-10-08 北京戴域生物技术有限公司 一种含有γδT细胞的药物组合物在治疗癌症中的用途
CN113480653B (zh) * 2021-08-06 2022-05-06 朱有建 一种含有γδT细胞的药物组合物在治疗癌症中的用途

Also Published As

Publication number Publication date
EP3316908A1 (en) 2018-05-09
WO2017004254A1 (en) 2017-01-05
TW201718641A (zh) 2017-06-01
EP3316908A4 (en) 2019-03-06
US20180193456A1 (en) 2018-07-12
BR112017027702A2 (pt) 2018-08-28
JP2018528759A (ja) 2018-10-04
CA2990450A1 (en) 2017-01-05
RU2018103192A3 (enExample) 2020-01-30
AU2016288192A1 (en) 2018-01-04
RU2018103192A (ru) 2019-07-30
HK1254048A1 (zh) 2019-07-12
KR20180021136A (ko) 2018-02-28

Similar Documents

Publication Publication Date Title
US11618786B2 (en) Anti-PD-L1 antibodies and variants
US11685783B2 (en) Anti-PD-1 antibodies
JP6691872B2 (ja) 抗上皮増殖因子受容体（ｅｇｆｒ）抗体
CN108025067A (zh) 抗血管内皮生长因子受体2（vegfr2）抗体
HK40109110A (en) Anti-pd-1 antibodies
HK40011908A (en) Anti-pd-1 antibodies
HK40011908B (en) Anti-pd-1 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180511